fbpx

molecules of the month

AZD0364

oral reversible ERK1/2 kinase inhibitor

combo eff. w/ MEKi in mKRAS model; in Ph. I

from historical kinase sel. data, SBDD + opt.

Mol. Cancer Ther. Dec. 3, 2020

AstraZeneca, Cambridge, UK

Structure of oral reversible ERK1/2 kinase inhibitor AZD0364
1 min read

AstraZeneca oral reversible ERK1/2 kinase inhibitor


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: